Lyophilized Pharmaceutical Compositions for Vaginal Delivery - Catalent EP3525765A1
Summary
The EPO published patent application EP3525765A1 for lyophilized pharmaceutical compositions designed for vaginal delivery. The patent was filed by Catalent U.K. Swindon Zydis Limited and names six inventors. The invention covers compositions classified under A61P therapeutic categories including antimicrobials and hormones, designated for protection across 31 European member states.
What changed
The EPO published a patent application for lyophilized pharmaceutical compositions intended for vaginal delivery. The composition uses freeze-drying technology and includes various excipients as indicated by the IPC classifications A61K 9/19, A61K 47/26, and A61K 47/36. The therapeutic applications span antimicrobials against bacteria (A61P 31/04), fungi (A61P 31/10), and viruses (A61P 31/12), as well as hormonal applications (A61P 15/16).
Pharmaceutical manufacturers and drug developers should monitor this patent for freedom-to-operate implications when developing vaginal delivery formulations. The broad designation across 31 European states makes this relevant for companies operating in the EU pharmaceutical space, particularly those working on lyophilized dosage forms or vaginal therapeutic products.
What to do next
- Monitor patent status for grant confirmation
- Review composition claims for potential licensing interest
- Assess applicability to vaginal delivery product pipeline
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LYOPHILIZED PHARMACEUTICAL COMPOSITIONS FOR VAGINAL DELIVERY
Publication EP3525765A1 Kind: A1 Apr 08, 2026
Applicants
Catalent U.K. Swindon Zydis Limited
Inventors
MASTO, Emilie, GARRETT, Lisa, BARRAT, Niamh, WONG, Yik Teng, MCLAUGHLIN, Rosaleen Theresa, BANBURY, Susan Gerrard
IPC Classifications
A61K 9/20 20060101AFI20250919BHEP A61K 9/00 20060101ALI20250919BHEP A61K 9/19 20060101ALI20250919BHEP A61K 47/26 20060101ALI20250919BHEP A61K 47/36 20060101ALI20250919BHEP A61K 47/42 20170101ALI20250919BHEP A61P 15/16 20060101ALI20250919BHEP A61P 31/04 20060101ALI20250919BHEP A61P 31/10 20060101ALI20250919BHEP A61P 31/12 20060101ALI20250919BHEP A61P 15/04 20060101ALI20250919BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.